← Leaderboards
Gerson David Hernandez
University Of Arizona
$2,098,361
Attributed
$6,295,083
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2022–25$2.5M$1.9M$1.3M$625K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$6,295,083 · 1
By mechanism
R01$6,295,083 · 1
Top collaborators
- Roberta Diaz Brinton4 shared
- Lisa Mosconi3 shared
- Schantel Williams1 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Roberta Diaz Brinton$56,323,258
- Patricia B Hoyer$6,157,492
- Cynthia A Thomson$8,364,016
- Lisa Mosconi$10,441,680
- Scott B Going$7,642,039
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposCritical PeriodBrain VolumeCognitionAging3 Year OldClinical Trials Cooperative GroupClinical TrialsClinical ResearchArterial Spin LabelingBlood-Based BiomarkerBrainBrain MetabolismAlternative HealthCognitive FunctionBreastAlzheimerâS Disease BiomarkerAgedAmericanCerebrovascular CirculationCerebrumClinical DevelopmentClinical EfficacyDaidzein
Grant awards (4)
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,301,410
R01 · FY2025 · AG
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,327,969
R01 · FY2024 · AG
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,544,481
R01 · FY2023 · AG
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$2,121,223
R01 · FY2022 · AG